Trial Profile
A Retrospective Study Assessing the Efficacy and Safety of Romiplostim for the Treatment of Chemotherapy-Induced Thrombocytopenia (CIT) in Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.